Suchergebnisse - "Lipari, Philip"

PubPharm (14)

1

Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models

enthalten in: Human molecular genetics | 2024

von Liu, G. | Lipari, P. | Mollin, A. | +21

2

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors

enthalten in: ACS medicinal chemistry letters | 2016

von Bogen, S. | Pan, W. | Gibeau, C. | +23

3

Kibdelomycin Is a Potent and Selective Agent against Toxigenic Clostridium difficile

enthalten in: Antimicrobial agents and chemotherapy | 2014

von Miesel, L. | Hecht, D. | Osmolski, J. | +10

4

Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile

enthalten in: Antimicrobial agents and chemotherapy | 2014

von Miesel, L. | Hecht, D. | Osmolski, J. | +10

5

A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts

enthalten in: Molecular cancer therapeutics | 2010

von Wang, Y. | Lipari, P. | Wang, X. | +7

6

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody

enthalten in: Molecular cancer therapeutics | 2005

von Wang, Y. | Hailey, J. | Williams, D. | +16

7

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody

enthalten in: Molecular cancer therapeutics | 2005

von Wang, Y. | Hailey, J. | Williams, D. | +6

8

Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction

enthalten in: Analytical biochemistry | 2004

von Zhang, R. | Mayhood, T. | Lipari, P. | +6

9

Fluorescence polarization assay and inhibitor design for MDM2-p53 interaction

enthalten in: Analytical biochemistry | 2004

von Zhang, R. | Mayhood, T. | Lipari, P. | +6

10

Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer

enthalten in: Cancer chemotherapy and pharmacology | 1999

von Gurnani, M. | Lipari, P. | Dell, J. | +2